We identified 53 infants aged 0-60 days with invasive pneumococcal disease (IPD) at 8 children's hospitals in the United States (2005States ( -2015. After the introduction of 13-valent pneumococcal conjugate vaccine (PCV13), IPD caused by PCV13 serotypes decreased ~30% providing some evidence of indirect protection. However, approximately 60% of IPD was still caused by PCV13 serotypes.
Streptococcus pneumoniae rarely colonizes the female urogenital tract or causes early-onset sepsis [1] . Moreover, the mean age of initial pneumococcal nasopharyngeal colonization has been reported to be 38 days [2] . In the United States, <1% of early-onset sepsis was attributed to S. pneumoniae from 2005 to 2014 [3] . Even though pneumococcal infections are rare in the neonatal period, they are associated with high morbidity and mortality [4] .
Infants aged ≤2 months are too young to receive pneumococcal immunization, thus their protection against invasive pneumococcal disease (IPD) depends on indirect protection via adequate vaccine coverage of older children. Currently, there is insufficient evidence to support maternal or neonatal pneumococcal immunization [5, 6] . Studies from the United States [7] , and England and Wales [8] , have shown evidence of indirect protection against IPD in infants aged 0-90 days after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). To our knowledge, the impact of the 13-valent PCV (PCV13) on IPD in young infants in the United States has not been assessed. Our objective was to compare the clinical and microbiologic characteristics of IPD in infants aged 0-60 days before and after the introduction of PCV13 at 8 children's hospitals in the United States.
METHODS
Since 1993, investigators from 8 children's hospitals (Houston, TX; Pittsburgh, PA; Little Rock, AR; San Diego, CA; Los Angeles, CA; Chicago, IL; Columbus, OH; and WinstonSalem, NC) have been prospectively identifying children with IPD. We identified infants aged 0-60 days with IPD from our database between January 1, 2005 and December 31, 2015. Invasive pneumococcal disease was defined as the isolation of S. pneumoniae from normally sterile body sites and/or intraoperative samples. The following samples were included in this study: blood, cerebrospinal fluid, pleural fluid, subperiosteal abscess of the mastoid, mastoid abscess, and neck abscess. The study was divided into 3 periods: pre-PCV13 (January 2005-December 2009), PCV13-transition year (2010), and post-PCV13 (January 2011-December 2015). Patients were also divided in early-onset IPD (0-6 days) and late-onset IPD (7-60 days). Infants aged 0-30 days were considered neonates. Clinical information was abstracted from medical records and recorded on a standardized case report form. Meningitis and pneumonia cases reported in this study were included in previous publications from our group [9, 10] . The study was approved by the Institutional Review Boards of each participating hospital.
Pneumococcal isolates were identified using standard methods in the microbiology laboratories of each hospital. All isolates were sent to a central laboratory (Infectious Disease Research Laboratory, Texas Children's Hospital, Houston, TX) for serotyping using commercially available antisera (Statens Serum Institut, Copenhagen, Denmark). Determination of minimum inhibitory concentration (MIC) for penicillin and ceftriaxone was performed by microbroth dilution with Mueller-Hinton media. The following susceptibility categories were used (meningeal MIC breakpoints): penicillin, ≤0.06 µg/mL = susceptible; and ceftriaxone, ≤0.5 µg/mL = susceptible.
Descriptive statistics were used to characterize the study population. Fisher's exact test and Mann-Whitney U test were used to compare categorical and continuous variables, respectively. A 2-tailed P value ≤.05 was considered statistically significant. IBM SPSS statistics version 22.0.0 was used for statistical analysis. Baseline characteristics were similar before and after the introduction of PCV13 (Table 1) . Overall, 17% (9 of 53) infants were ≤6 days old, 9% (5 of 53) were 7-30 days old, and 74% (39 of 53) were 31-60 days old. Invasive pneumococcal disease within the first 48 hours of life represented 43% (6 of 14) of neonatal IPD. Remarkably, all premature infants developed late-onset IPD.
RESULTS

We identified
The most common clinical syndrome was bacteremia without focus 43% (23 of 53), followed by meningitis 32% (17 of 53), mastoiditis 11% (6 of 53), and pneumonia 9% (5 of 53). One patient presented with a neck abscess, and one other patient presented with with facial cellulitis and bacteremia. Eighty-two percent (14 of 17) of patients with meningitis and 60% (3 of 5) of patients with pneumonia were bacteremic. None of the patients with mastoiditis presented with bacteremia. The distribution of clinical syndromes remained unchanged after the introduction of PCV13 (Table 1) . Meningitis was more commonly observed among infants with early-onset IPD than among infants with late-onset IPD (67% vs 25%, P = .02) (Supplementary Figure 1) . The case-fatality rate was 11% (1 of 9) in infants aged ≤6 days, 0% in infants aged 7-30 days, and 3% (1 of 39) in infants aged 31-60 days.
Forty-nine isolates were available for serotyping and antibiotic susceptibility testing. Overall, the most common serotypes were 19A (11 of 49, 22%), 7F (9 of 49, 18%), and 3 ( Overall, 74% (36 of 49) of isolates were penicillin susceptible and 94% (46 of 49) were ceftriaxone susceptible. Penicillin susceptibility decreased from 85% (23 of 27) to 59% (10 of 17) after the introduction of PCV13 (P = .07). Serotypes 19A, 35B, 15A, 6C, and 6B were responsible for penicillin-nonsusceptible isolates (Supplementary Figure 2) . Most patients with meningitis (80%, 12 of 15) had isolates susceptible to penicillin.
DISCUSSION
In our study, after the introduction of PCV13, the number of cases of IPD caused by PCV13 serotypes in infants aged 0-60 days decreased approximately 30% with no change in the distribution of clinical syndromes. Still, in 2011-2015, approximately 60% of IPD was caused by PCV13 serotypes (19A, 19F, 3) . Infants with early-onset IPD were mainly affected by [7] . This reduction was driven by a substantial decrease in IPD caused by PCV7 serotypes, suggesting indirect protection of this unvaccinated age group. In England and Wales, the incidence of IPD caused by PCV7 serotypes in infants aged 0-90 days also declined after the introduction of PCV7 [8] . In our study, although 82% of IPD cases in infants aged 0-60 days were caused by PCV13 serotypes in 2005-2009, we observed a decrease of only 28% in IPD caused by PCV13 serotypes in the 5 years after the introduction of PCV13. Given the vaccination coverage of 82%-84% for ≥4 doses of PCV13 among children from 2011 to 2015 in the United States [11] , a more pronounced reduction in IPD caused by PCV13 serotypes among infants aged 0-60 days might have been expected. Among the states where our surveillance sites are located, only Arkansas (76.1%) and Ohio (79.1%) had vaccination coverage lower than the national average in 2015 [11] . Thus, the nonsignificant reduction in IPD caused by PCV13 serotypes is more likely secondary to our small sample size than to low vaccination coverage at the local level.
The non-PCV13 serotypes observed among infants aged 0-60 days in our study are consistent with non-PCV13 serotypes causing IPD in older children [12] . Non-PCV13 serotypes 35B, 15A, and 6C contributed to the decrease in penicillin-susceptible isolates in 2011-2015, but the highest penicillin MICs (2 and 4 µg/mL) were still observed among isolates of serotype 19A post-PCV13.
In our study, most neonatal IPD cases occurred during the first week of life (64%), predominantly within the first 48 hours. This is similar to observations from other groups in which ~70% of neonatal IPD occurred within the first week of life [7, 13] . Our current results differ from our previous study from the pre-PCV era, in which most neonatal IPD cases occurred during the third week of life [4] , and a pre-PCV13 study from Utah [14] . Despite our low percentage (7%) of premature infants, our early-onset IPD results were similar to studies with a higher percentage of premature infants (23%) [7, 8] . Pneumococcal immunization given at birth [6] may not prevent most early-onset IPD; however, it may be beneficial to prevent late-onset IPD. Thus, future neonatal IPD prevention strategies should also focus on maternal risk factors and/or maternal immunization. It is possible that childhood immunization programs for PCV may provide some passive immunity for neonates born to young mothers immunized before 4-6 years of age.
We reported pneumococcal meningitis significantly more associated with early-onset sepsis than late-onset sepsis, contrary to other reports [7, 8, 13] . Meningitis is also more common in late-onset rather than early-onset group B streptococcal disease. The reason for the high proportion of meningitis among infants aged ≤6 days in our study is not clear. None of those infants were premature, and cases were not associated with a particular serotype or antibiotic-resistant isolates.
Some limitations should be considered. Our surveillance study is not population-based and we were not able to calculate incidence rates. Perinatal risk factors and relevant family structure information were not evaluated. Despite the multicenter design of our study, the sample size was small and it limited the statistical power of our analysis.
CONCLUSIONS
After the introduction of PCV13, we observed a decline of ~30% in IPD due to PCV13 serotypes in infants aged 0-60 days. In 2011-2015, however, approximately 60% of IPD was still caused by PCV13 serotypes. No evidence of serotype replacement was observed. Infants aged 0-60 days remain vulnerable to PCV13 serotypes despite some evidence of indirect protection. Ongoing surveillance studies and evaluation of other strategies to protect these young infants are necessary.
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